ALBUQUERQUE, N.M., Sept.13 /PRNewswire/ -- Exagen Diagnostics, Inc., an
emerging leader in the rapid identification and productization of practical,
genomic markers for prognostic testing, today announced that it has formed an
advisory board to provide input on the company's genomic marker programs and
clinical trials that impact treatment and management of hepatitis C infection
(HCV). The board consists of four physicians, all of whom are among the
nation's leading experts in the clinical assessment of new therapeutic
alternatives for HCV.
"We have initiated clinical discovery studies to define the best genomic
markers for HCV prognostic testing. These markers will identify those
patients most likely to benefit from treatment with interferon and ribviran
and those at greatest risk of liver damage," said Waneta Tuttle, Ph.D., Exagen
president and CEO. "We are very pleased to be working closely with this
outstanding group of physicians to ensure the utmost effectiveness of the
programs and trials we undertake for HCV."
Members of Exagen's advisory board include:
* Sanjeev Arora, M.D., FACP, advisory board chairperson, and executive
vice chairman, department of internal medicine, at University of New
Mexico Health Sciences Center (UNMHSC). Since 2001, he has served as
principal investigator for more than 17 clinical trials focused on
ribaviran treatment for chronic HCV.
* Michael Fried, M.D., professor of medicine and director of hepatology
at the University of North Carolina at Chapel Hill. Dr. Fried has
been the principal investigator on numerous Phase I, II and III
clinical trials of various antiviral agents for chronic hepatitis B
* Robert Gish, M.D., divisional director of the Division of Hepatology
and Complex GI at California Pacific Medical Center and medical
director of the Liver Transplant Program at CPMC. He also serves as
associate clinical professor of medicine at the University of
California, San Francisco. Since 1985, he has served as principle
investigator for more than 50 research studies focused on various
treatment methods for hepatitis B and C.
* Paul Pockros, M.D., division head, Gastroenterology/Hepatology at
Scripps Clinic in La Jolla, Calif. He currently practices general
gastroenterology and has a special interest in liver disease. He is a
principal or co-investigator in a large number of clinical trials for
treatment of chronic liver disease, especially for hepatitis B and C.
"We are pleased to help guide Exagen by providing input regarding unmet
needs for prognostic tests," said Dr. Arora. "Exagen's work has the potential
to significantly advance HCV disease management, benefiting patients and
helping guide physicians in the future."
The number of people infected with HCV worldwide is approaching
200 million, including four million people in the United States. HCV accounts
for up to half of all cases of cirrhosis, end-stage liver disease and liver
cancer. The standard regimen of interferon and ribavirin is costly and
plagued by side effects.
About Exagen Diagnostics, Inc.
As an emerging leader in prognostic testing, Exagen Diagnostics is
uniquely able to define small sets of genomic markers that are more accurate
than other approaches, whether for breast cancer, infectious disease or other
indications. Exagen's proprietary discovery and implementation technologies
enable the rapid identification and productization of optimized DNA or RNA
genomic marker sets for prognostic or predictive testing, either for
diagnostic testing by reference laboratories or for pharmaceutical R&D
purposes. For more information, visit www.exagendiagnostics.com.
SOURCE Exagen Diagnostics, Inc.